5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Superficial Basal Cell Carcinoma Clinical Trial

Official title:

Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05381597
• Other study ID #: H-42421
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: October 15, 2022
• Est. completion date: June 2025

Study information

• Verified date: January 2024
• Source: Boston University
• Contact: Frederick Gibson, MD
• Phone: (617) 358-9700
• Email: frederick.gibson[@]bmc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will compare the application of two different creams for the treatment of low-risk skin cancers-superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis). 5-Fluorouracil cream is currently FDA approved for the treatment of superficial basal cell carcinoma and is routinely used by dermatologists across the country and at Boston Medical Center (BMC) for SCCis. The normal treatment regimen is 4 weeks of the 5-fluorouracil cream for both skin cancers. The application of a compounded cream consisting of 1:1 ratio 5-fluorouracil with calcipotriene will be tested. This combination cream has been shown to clear pre-skin cancers called actinic keratoses and prevent future skin cancers from developing. This combination cream for 7-14 days to see if this shorter treatment course provides clearance of the 2 types of skin cancer. This combination cream is successfully used in this manner to treat other subtypes of related skin cancers. This will be a pilot study with The primary endpoint for this pilot randomized single blinded clinical trial will be the response to treatment (yes versus no). The lesions will be assessed clinically for clearance of cancer, as would normally be done and is consistent with how comparable studies have assessed clearance. Participants will be followed closely afterwards for three years with visits at 6 months, which does not vary from standard practice. If the lesions are not clear of cancer or equivocal clinically, the lesions will be re-biopsied and normal standard of care procedure will take place.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• English-speaking
• Having a previously untreated, biopsy-proven Superficial Basal Cell Carcinoma (sBCC) or Squamous Cell Carcinoma in Situ (SCCis) of the skin <2 cm on the scalp, trunk, neck, or extremities, excluding hands, feet, and genitalia
• Having a previously untreated, biopsy-proven sBCC or SCCis on the face, hands, feet, and genitalia who decline surgery or are otherwise not surgical candidates
• Willing to undergo all protocol requirements and attend study-specific follow up clinic visits in addition to routine follow up visits
• Participants may have multiple lesions enrolled in the study so long as the individual lesions are greater than 2 cm from each other
• If a woman is of childbearing potential, the participant must be willing to take a pregnancy test before starting treatment and be on some form of birth control while receiving treatment. Birth control can include abstinence, oral contraceptive pill, intrauterine device, implanted birth control device, birth control patch, or the vaginal ring. The patient does not need to be on any form of birth control after they end therapy.

Exclusion Criteria:

• Current or prior field treatment within 2 cm of the target BCC or SCCis
• Periorbital lesions
• Lesions that have been previously treated
• Known allergy to any of the study medication ingredients
• History of solid organ transplant or current immunosuppression
• Genetic disorders associated with high skin cancer risk
• Arsenic exposure
• Cutaneous T-cell lymphoma
• Current or prior radiation therapy at the site of the sBCC or SCCis
• Women who are pregnant or currently breastfeeding
• Prior psoralen plus Ultraviolet light (UVA) treatment at the site
• Very high mortality risk at the start of the study
• Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
• Demonstrated hypercalcemia or evidence of vitamin D toxicity
• Lesions that extend into the oral, nasal or genital mucosa

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma in Situ
• Carcinoma, Basal Cell
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma in Situ
• Superficial Basal Cell Carcinoma

Intervention

Drug:
• Combination cream of 5-fluorouracil and calcipotriene
Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
• 5-fluorouracil cream
Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.

Locations

Country	Name	City	State
United States	Boston Medical Center Dermatology Clinic	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Boston University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clearance rate of cancer lesions at 3 months	Clearance rate is defined as the percentage of lesions that are free of cancer based on clinical assessments which will be performed by the patient's dermatologist and via photos from a standardized full frontal angle.	3 months
Primary	Clearance rate of cancer lesions at 3 years	Clearance rate is defined as the percentage of lesions that are free of cancer based on clinical assessments which will be performed by the patient's dermatologist and via photos from a standardized full frontal angle.	3 years
Secondary	Percent of participants that experience pain during treatment	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will rate their pain from 1 to 5 where 1=no pain, 2= very mild, 3=mild, 4=moderate (requiring pain medication), 5=severe (requiring pain medication or physician contact). The number of participants with scores of 2 or higher will be divided by all participants.	3 months
Secondary	Severity of pain during treatment	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will rate their pain from 1 to 5 where 1=no pain, 2= very mild, 3=mild, 4=moderate (requiring pain medication), 5=severe (requiring pain medication or physician contact). Mean pain ratings will be calculated with higher mean scores suggesting more severe pain.	3 months
Secondary	Percent of participants that experience redness during treatment	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will rate their overall redness from 1 to 5 where 1=no redness, 2= very minimal, 3=minimal, 4=moderate, 5=severe. The number of participants with scores of 2 or higher will be divided by all participants.	3 months
Secondary	Severity of redness during treatment	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will rate their overall redness from 1 to 5 where 1=no redness, 2= very minimal, 3=minimal, 4=moderate, 5=severe. Mean redness ratings will be calculated with higher mean scores suggesting more severe redness.	3 months
Secondary	Day of worst redness	For participants who experienced any redness, the mean day after treatment when the redness was worst will be calculated.	3 months
Secondary	Percent of participants who experienced scaling/flaking	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will be asked if they experienced any scaling/flaking. The number of participants who responded 'yes' will be divided by all participants.	3 months
Secondary	Percent of participants who experienced skin itching	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will be asked if they experienced any skin itching. The number of participants who responded 'yes' will be divided by all participants.	3 months
Secondary	Percent of participants who experienced skin burning	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will be asked if they experienced any skin burning. The number of participants who responded 'yes' will be divided by all participants.	3 months
Secondary	Participant compliance with treatment	Compliance with treatment will be assessed by weighing the medicine tubes after treatment completion and comparing the weight, estimated in grams from fingertip units (FTU), with the expected weight based on the how much medicine should have been used given the treatment regimen. The closer this difference is to zero, the greater the compliance.	3 months
Secondary	Participant satisfaction with treatment	Based on responses to an investigator-developed survey completed by each participant within 5 days of treatment completion, participants will rate their satisfaction with the treatment from 1 to 5 where 1=very dissatisfied, 2= dissatisfied, 3=neutral, 4=satisfied, 5=very satisfied. Mean satisfaction ratings will be calculated with higher mean scores suggesting more treatment satisfaction.	3 months
Secondary	Recurrence rate of cancer lesions at 1 year	The recurrence rate is the percentage of cancer lesions that recur which is the number that recur out of the number cleared.	1 year
Secondary	Recurrence rate of cancer lesions at 3 years	The recurrence rate is the percentage of cancer lesions that recur which is the number that recur out of the number cleared.	3 years